{
    "pmcid": "9512078",
    "qa_pairs": {
        "How was the VHH-IgA1.1 nanobody optimized for increased affinity?": [
            "Using AHEAD technology.",
            "Through random mutagenesis.",
            "By increasing the size of the nanobody.",
            "By fusing with a different Fc region."
        ],
        "What is a key benefit of producing VHH-IgA1.1 in Pichia pastoris?": [
            "It is cost-effective and scalable.",
            "It enhances the nanobody's binding affinity.",
            "It allows for rapid degradation in the body.",
            "It increases the molecular weight for better stability."
        ],
        "What is the primary advantage of using nanobodies like VHH-IgA1.1 against hypervariable pathogens such as viruses?": [
            "They can access conserved and recessed epitopes on viral proteins.",
            "They have a higher molecular weight than conventional antibodies.",
            "They are derived from human antibodies, making them more compatible.",
            "They require complex production systems, increasing specificity."
        ],
        "What is the significance of fusing VHH1.1 with the Fc region of human IgA1?": [
            "It enhances the binding and neutralization potency, especially against the Omicron variant.",
            "It reduces the production cost significantly.",
            "It allows the nanobody to be administered orally.",
            "It decreases the molecular weight for better tissue penetration."
        ],
        "Which delivery method is used for VHH-IgA1.1 to provide direct mucosal immunity?": [
            "Intranasal administration.",
            "Intravenous injection.",
            "Oral administration.",
            "Subcutaneous injection."
        ]
    }
}